Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuromuscular and Bone Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRP4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRP4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View LRP4 Products |
| Gene Delivery | LRP4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LRP4 Products |
| Benchmark Ab | Anti-LRP4 (Sequence of clinical benchmark) Recombinant positive control. |
View LRP4 Products |
| Validator | LRP4 siRNA Set For knockdown verification. |
View LRP4 Products |
| Related Target A | MuSK Muscle-Specific Kinase; essential co-receptor in Agrin-LRP4-MuSK signaling pathway for neuromuscular junction (NMJ) maintenance. |
View MuSK Products |
| Related Target B | SOST Sclerostin; LRP4 acts as a co-receptor for Sclerostin to inhibit Wnt/beta-catenin signaling in bone metabolism. |
View SOST Products |
| Related Target C | USAG1 Uterine sensitization-associated gene-1 (also known as SOSTDC1); interacts with LRP4 to modulate Wnt signaling in tooth and bone development. |
View USAG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native post-translational modifications of LRP4 large ECD | HEK293 mammalian expression system ensures native glycosylation and correct disulfide bond folding. |
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus LRP4 ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LRP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRP4 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeted monoclonal antibodies (mAbs) and protein therapeutics. As first-generation therapies for neuromuscular disorders and bone density regulation reach preclinical and early clinical stages, the next wave of R&D is targeting highly specific modulation of the LRP4-MuSK complex and the LRP4-SOST/USAG1 bone regulatory pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Agonistic) | Academic Spin-offs, Neuromuscular Biotechs | Myasthenia Gravis (MG), ALS, Sarcopenia | MuSK Activation & Phosphorylation Assays (Need high-purity LRP4 and MuSK ECD) |
| Monoclonal Antibodies (Antagonistic) | Bone Health Specialists, Pharmaceutical Consortia | Osteoporosis, Bone Fractures | LRP4-SOST / LRP4-USAG1 Interaction Blocking Assay (Need high-purity SOST/USAG1 and LRP4) |
| Gene Therapy / Lentivirus | Gene Therapy Startups | Congenital Myasthenic Syndromes (CMS) | Stable Cell Line Construction (Need Lentivirus for high-efficiency transduction) |